Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Sristi Jayaswal

HISTORICAL FACTS: Is biogen stock underperforming the nasdaq | History Defined

Biogen Inc. (BIIB) is one of the world’s leading biotechnology companies. Valued at $32.5 billion by market cap, the company pioneers therapies for neurological and neurodegenerative diseases globally. Renowned for breakthroughs like TECFIDERA, SPINRAZA, ADUHELM, and OCREVUS, Biogen leads in treating MS, Alzheimer's, and more. Its robust pipeline includes innovations for Parkinson's, neuropsychiatric disorders, and biosimilars. Collaborations with Acorda, Denali, and Genentech bolster its research prowess. Founded in 1978, Biogen continues to push boundaries from its Cambridge, Massachusetts headquarters, shaping the future of neurology and immunology with cutting-edge treatments and partnerships.

Companies worth $10 billion or more are generally described as “large-cap stocks,” Biogen fits that category, boasting a market cap that exceeds this threshold, reflecting its size, significant influence, and dominance in the biotech industry. Biogen became a large-cap stock through pioneering biotech breakthroughs and strong market performance in neurology and immunology, attracting investor confidence and boosting its market cap.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.